Glucagon/GLP-1 receptor co-agonists

• US 10,174,093 B2
• Filed: 08/07/2017
• Issued: 01/08/2019
• Est. Priority Date: 06/22/2011
• Status: Expired due to Fees

• Current Assignee: Indiana University Research & Technology Corporation (Indiana University)
• Original Assignee: Indiana University Research & Technology Corporation (Indiana University)
• Inventors: DiMarchi, Richard D., Smiley, David L.
• Primary Examiner(s): Chandra, Gyan
• Application Number:
  US15/670,200
• Publication Number:
  US 20170349642A1
• Time in Patent Office: 519 Days
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 49/00 Preparations for testing in vivo
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/605 Glucagons
• CPC Class Codes: C07K 16/283 against Fc-receptors, e.g. CD16, CD32, CD64 CD23 C07K16/2851
• CPC Class Codes: C07K 2319/00 : Fusion polypeptide
• CPC Class Codes: C07K 2319/30 : Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/33 : fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
• CPC Class Codes: G01N 2333/605 : Glucagons
• CPC Class Codes: G01N 2800/042 : Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 2800/085 : Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
• CPC Class Codes: G01N 2800/2821 : Alzheimer
• CPC Class Codes: G01N 2800/2835 : Movement disorders, e.g. Parkinson, Huntington, Tourette
• CPC Class Codes: G01N 33/74 : involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.

Claims

1. A peptide comprising the amino acid sequence of:

SEQ ID NO;

13 or a pharmaceutically acceptable salt thereof.

2. A peptide of claim 1 consisting of the amino acid sequence of SEQ ID NO:

13, or a pharmaceutically acceptable salt thereof.

3. A variant peptide that differs from the amino acid sequence of the peptide of claim 1 in that the variant peptide comprises one or more of the following features:

a) an acylated amino acid or an alkylated amino acid at position 10;

b) an amino acid at any one of positions 1 through 29 is replaced with the corresponding amino acid of native glucagon (SEQ ID NO;

     1) at that position;

c) or any combinations thereof;

or a pharmaceutically acceptable salt thereof,

wherein the variant peptide exhibits enhanced activity at the GLP-1 receptor, as compared to native glucagon, and exhibits at least 100-fold greater selectivity for the human GLP-1 receptor versus the GIP receptor, or a pharmaceutically acceptable salt thereof.

4. The variant peptide of claim 3, comprising (i) an acylated or alkylated amino acid which comprises a C8 to C20 alkyl chain, a C12to C18 alkyl chain, or a C14 or C16 alkyl chain, or a pharmaceutically acceptable salt thereof, (ii) an acylated or alkylated amino acid which an acylated or alkylated amino acid of Lys, or a pharmaceutically acceptable salt thereof, (iii) an acylated or alkylated amino acid, wherein the acyl group or alkyl group is covalently attached to the amino acid via a spacer, optionally, wherein the spacer is an amino acid or a dipeptide, or a pharmaceutically acceptable salt thereof, (iv) or a combination thereof.

5. The variant peptide of claim 4, wherein the spacer comprises one or two acidic residues, or a pharmaceutically acceptable salt thereof.

6. A conjugate comprising a variant peptide of claim 3 conjugated to a heterologous moiety, or a pharmaceutically acceptable salt thereof, wherein the conjugate exhibits enhanced activity at the GLP-1 receptor, as compared to native glucagon, and exhibits at least 100-fold greater selectivity for the human GLP-1 receptor versus the GIP receptor.

7. The conjugate of claim 6, wherein the heterologous moiety comprises one or more of:

a peptide, a polypeptide, a nucleic acid molecule, an antibody or fragment thereof, a polymer, a quantum dot, a small molecule, a toxin, a diagnostic agent, or a pharmaceutically acceptable salt thereof.

8. The conjugate of claim 7, comprising an extension of 1-21 amino acids C-terminal to the amino acid at position 31 of the variant peptide, wherein the extension is selected from the group consisting of:

Gly, Glu, Cys, Gly-Gly, Gly-Glu, GPSSGAPPPS (SEQ ID NO;

     9) or GGPSSGAPPPS (SEQ ID NO;

10), or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising the variant peptide of claim 3, or a pharmaceutically acceptable salt thereof.

10. A conjugate comprising a peptide of claim 1 conjugated to a heterologous moiety, or a pharmaceutically acceptable salt thereof, wherein the conjugate exhibits enhanced activity at the GLP-1 receptor, as compared to native glucagon, and exhibits at least 100-fold greater selectivity for the human GLP-1 receptor versus the GIP receptor.

11. The conjugate of claim 10, wherein the heterologous moiety comprises one or more of:

a peptide, a polypeptide, a nucleic acid molecule, an antibody or fragment thereof, a polymer, a quantum dot, a small molecule, a toxin, a diagnostic agent, or a pharmaceutically acceptable salt thereof.

12. The conjugate of claim 11, comprising an extension of 1-21 amino acids C-terminal to the amino acid at position 31 of the peptide or variant peptide, or a pharmaceutically acceptable salt thereof.

13. The conjugate of claim 12, wherein the extension is selected from the group consisting of:

Gly, Glu, Cys, Gly-Gly, Gly-Glu, GPSSGAPPPS (SEQ ID NO;

     9) or GGPSSGAPPPS (SEQ ID NO;

     10), or a pharmaceutically acceptable salt thereof.

14. A dimer or multimer comprising a peptide of claim 1, or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising the peptide of claim 1, or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical composition of claim 15, further comprising an anti-diabetic or anti-obesity agent.

17. The pharmaceutical composition of claim 16 wherein said anti-diabetic agent is selected from the group consisting of insulin, leptin, Peptide YY (PYY), Pancreatic Peptide (PP), fibroblast growth factor 21 (FGF21), Y2Y4 receptor agonists, tolbutamide (Orinase), acetohexamide (Dymelor), tolazamide (Tolinase), chlorpropamide (Diabinese), glipizide (Glucotrol), glyburide (Diabeta, Micronase, Glynase), glimepiride (Amaryl), or gliclazide (Diamicron), repaglinide (Prandin), nateglinide (Starlix), metformin (Glucophage), phenformin, rosiglitazone (Avandia), pioglitazone (Actos), troglitazone (Rezulin), miglitol (Glyset), acarbose (Precose/Glucobay), exenatide (Byetta), pramlintide, vildagliptin, sitagliptin, glucokinase activators (GKA), glucagon receptor antagonists (GRA), and FBPase (fructose 1,6-bisphosphatase) inhibitors.

18. The pharmaceutical composition of claim 16 wherein said anti-obesity agent is selected from the group consisting of phenethylamine type stimulants, phentermine, fenfluramine, dexfenfluramine, diethylpropion (Tenuate®

), phendimetrazine (Prelu-2®

, Bontril®

), benzphetamine (Didrex®

), sibutramine (Meridia®

, Reductil®

);

rimonabant (Acomplia®

), oxyntomodulin, fluoxetine hydrochloride (Prozac), Qnexa, Excalia, Contrave, XENICAL (Orlistat), Cetilistat, or GT 389-255.

19. A method of treating a disease or medical condition in a patient in need thereof, wherein the disease or medical condition is selected from the group consisting of:

metabolic syndrome, diabetes, obesity, and liver steatosis, comprising administering to the patient the pharmaceutical composition of claim 15 in an amount effective to treat the disease or medical condition.